The Finance of Immunogenicity

Managing immunogenicity risk should be a core focus in drug development. ProImmune’s CEO Nik Schwabe explains why.

ProPresent® – ProImmune’s Antigen Presentation Assay

Dr Nikolai Schwabe introduces the ProPresent antigen presentation assay and some of its applications in the field of immunogenicity.

HLA Tissue Typing

Dr Briana Betz explains the importance of understanding the HLA types of your study cohort, and how ProImmune can help you.